This article is more than 5 years old. Information may no longer be current.
Baseline vision, central retinal thickness predictive of bevacizumab efficacy
Click Here to Manage Email Alerts
INDIAN WELLS, Calif. — Baseline best corrected visual acuity and central retinal thickness are positive predictive factors of successfully treating subfoveal neovascular age-related macular degeneration with bevacizumab, according to a speaker here.
At the American Society of Retina Specialists annual meeting, Evelyn X. Fu, MD, presented results from a retrospective study of 73 eyes treated with Avastin (bevacizumab, Genentech) for neovascular AMD. Specifically, Dr. Fu and colleagues investigated any parameters predictive of visual and anatomical outcomes in these patients.
Patients had an average baseline visual acuity of 20/177 and an average baseline central retinal thickness of 434 µm.
"More patients with vision worse than 20/100 improved compared to those [with vision] better than 20/100," Dr. Fu said. "Additionally, fewer patients with vision less than 20/100 declined more than three lines."
Regarding reductions in central retinal thickness, patients with a baseline central retinal thickness more than 400 µm showed the most improvement.
Additionally, "patients with occult-only [choroidal neovascularization] showed the least amount of improvement, and patients with any prior treatment showed the least amount of improvement in terms of central retinal thickness reduction," Dr. Fu noted.